InterTAN IM Nail Versus Sliding Hip Screw in Geriatric Fractures

NCT ID: NCT00664950

Last Updated: 2015-09-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 240 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-11-30
• Study Completion Date: 2014-12-31

Brief Summary

Elderly patients with an intertrochanteric hip fracture will be randomized to receive either a sliding hip screw (SHS) (control group) or InterTAN intermedullary nail (IMN) (experimental group) for surgical fixation of their hip fracture. This study will assess functional and mortality outcomes for elderly patients with hip fractures.

Detailed Description

Outcome after hip fracture in the elderly is generally poor. According to the World Health Organization, fracture of the hip is associated with 20 % 1-year mortality and 50 % loss of function33. However, the high mortality and loss of function can be improved. For example, numerous studies have shown improvement in relevant outcomes when interventions such as improved thromboprophylaxis, care pathways and timely surgery are achieved. Up to 50 % decreases in mortality can be achieved with these interventions1,2,3.

While improvements in perioperative care can improve outcome, the benefit of newer surgical techniques and implants is less clear. This is well demonstrated in the case of intertrochanteric fractures. Intertrochanteric fractures are those in which the primary fracture line occurs between the greater and lesser trochanter and include approximately 50 % of all hip fractures. Many surgical implants have been developed for this common fracture pattern; in general, the conventional implant is a sliding hip screw (SHS) in which a plate is fixed to the lateral cortex of the femur, distal to the fracture; and a large-diameter screw is placed in the centre of the femoral head, proximal to the fracture. The screw and plate slide relative to one another, permitting compression of the fracture and facilitating bone healing. In contrast, the newer implants are typically intramedullary nail designs (IMN), in which a metal nail is placed within the canal of the femur and a large-diameter screw is placed in the centre of the femoral head. The theoretical advantage of newer designs is based upon, first, an improved stability of the implant, allowing earlier and more aggressive mobilization; and second, a less invasive surgical procedure to minimize blood loss. Nonetheless, repeated trials and meta-analyses have failed to demonstrate an advantage to the IMN designs compared to SHS. In fact, perioperative complications seem to be higher using the IMN designs4,5.

There are two primary reasons why IMN designs have not translated into improved results to date. First, perioperative complications, especially fractures of the femur, are more common with current IMN designs. Second, the supposed improved stability conferred by these devices may not actually be achieved. Current IMN designs retain the original concept of a single screw in the femoral head, which does not prevent rotation of the femoral head - a common reason for implant failure. As well, most current IMN designs permit unrestricted axial shortening of the femur, which may lead to significant leg length changes and alter gait.

A new implant has been designed to take advantage of the inherent theoretical strengths of IMN designs and improve upon current design flaws. The InterTAN device (IT) has been designed to improve stability after fixation of intertrochanteric fractures. This device has a double proximal hip screw, to achieve rotational control; improved implant geometry, to improve immediate stability; and immediate compression to achieve stability while avoiding uncontrolled leg length changes. The IT device retains the percutaneous insertion technique of other IMN devices and simplifies insertion with redesigned instrumentation. The InterTAN device is the first device designed specifically to provide enhanced stability to intertrochanteric fractures and seems to offer significant promise compared to other IM designs.

The InterTAN device has not, as of yet, been compared to conventional surgical techniques. According to the Cochrane Database Reviews, "Any new design should be evaluated in a randomised comparison with the sliding hip screw."

Conditions

Hip Fractures

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SHS

sliding hip screw

Group Type: ACTIVE_COMPARATOR

sliding hip screw

Intervention Type: DEVICE

surgical repair of hip fracture using conventional sliding hip screw

InterTAn IM Nail

interTAN IM nail

Group Type: ACTIVE_COMPARATOR

IntertAn IM nail

Intervention Type: DEVICE

interTAN IM nail

Interventions

sliding hip screw

surgical repair of hip fracture using conventional sliding hip screw

Intervention Type: DEVICE

IntertAn IM nail

interTAN IM nail

Intervention Type: DEVICE

Other Intervention Names

InterTAn

Eligibility Criteria

Inclusion Criteria

1. Age 55 years or greater*

2. Intertrochanteric fracture amenable to treatment by sliding hip screw or intramedullary nail fixation

3. Previously ambulatory (defined as not usually requiring a wheelchair for ambulation)*

4. Provision of informed consent*

5. Surgery performed within 72 hours of admission

Exclusion Criteria

1. Cognitive or language barriers that would limit completion of assessment tests in English*

2. Anticipated problems with follow-up in the judgment of the resident, or attending surgeon (e.g of no fixed address)*

3. Surgeon refusal to randomize patient

4. Pathologic fractures

5. Polytrauma that would impact functional assessments in the opinion of the surgeon

• Minimum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Orthopaedic Research Foundation

OTHER

Sponsor Role: collaborator

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

Sponsor Role: lead

Responsible Party

David Sanders

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

David Sanders, MD

Role: PRINCIPAL_INVESTIGATOR

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Dianne Bryant

Role: PRINCIPAL_INVESTIGATOR

Western University, Canada

Locations

Saint John Regional Hosptial

Saint John, New Brunswick, Canada

London Health Sciences Centre

London, Ontario, Canada

Ottawa Civic Hospital

Ottawa, Ontario, Canada

Countries

Canada

Other Identifiers

13619

Identifier Type: OTHER

Identifier Source: secondary_id

R-08-002

Identifier Type: -

Identifier Source: org_study_id